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Two articles in this month’s issue of the Journal highlight pro-
gress in understanding intracellular pathways of ﬁbrogenesis
due to hepatitis C virus (HCV), and a potential new approach to
imaging hepatic ﬁbrosis using magnetic resonance imaging
(MRI). Together, they illustrate the steady, successful assault on
the problem of hepatic ﬁbrosis, both in uncovering its mecha-
nisms and advancing its clinical management.
The study by Chouteau and colleagues from Paris demon-
strates that hepatocyte-speciﬁc expression of the HCV structural
and non-structural proteins increases the degree of ﬁbrosis and
stimulates the hepatic progenitor cell response in mice with liver
injury due to CCl4, a standard hepatotoxin. The original trans-
genic model was developed by Stanley Lemon’s group several
years ago [1], which demonstrated progressive steatosis and then
adenomas and carcinomas as the animals aged. Expression levels
of the HCV proteins were within the range associated with native
infection, and there was virtually no baseline inﬂammation, indi-
cating the lack of an immune response, and no ﬁbrosis. However,
the transgenic livers expressed greater levels of lipid peroxida-
tion products, implicating interaction of HCV core protein with
some cellular components, possibly mitochondria or the intracel-
lular domains of a tumor necrosis factor alpha receptor [1].
In the Chouteau study, animals were given CCl4 for 4 weeks,
an intermediate dosing regimen that is not sufﬁcient to induce
cirrhosis, and while ﬁbrosis was present in both the control and
HCV transgenic mice, mice with transgenic HCV protein expres-
sion had more ﬁbrosis, with an increased ductular reaction asso-
ciated with greater numbers of hepatic progenitor cells, as
assessed by CK-19 staining. At the same time, hepatocyte replica-
tion was reduced based on Ki67 staining, and there was a strong
inverse relationship between the number of Ki67-positive hepa-
tocytes and the extent of ﬁbrosis, indicating that impaired hepa-
tocyte regeneration was associated with increased ﬁbrosis. There
was no difference in inﬂammation between control and HCV
transgenic animals. Mechanistic insights were limited to evi-
dence of increased baseline and CCl4-induced levels of reactiveJournal of Hepatology 20
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mRNA expression in these same animals, with no change in sev-
eral other MMP transcripts.
These results are intriguing for at least two reasons. First, they
reinforce evidence of the disruptive effect of HCV proteins on
hepatocyte homeostasis that leads to enhanced oxidant stress,
with greater susceptibility to ﬁbrosis. Second, they reframe the
idea that replicative block of hepatocytes, from a variety of
causes, drives the hepatic progenitor response, which in turn is
linked to increased ﬁbrosis in animals and humans [2–4].
It remains unclear whether the response of hepatocytes to
transgenic HCV protein expression is identical to that of native
infection. While the levels of HCV proteins are reportedly compa-
rable to infection, the response of hepatocytes suggest activation
of the unfolded protein response (UPR), a cellular mechanism
that manages misfolded or excessive accumulation of proteins
[5]; thus, the mitochondrial involvement, leading to steatosis
and lipid peroxidation could reﬂect the protective response of a
cell confronted with a misfolded HCV protein that is not seen
in native infection. It would be extremely interesting to evaluate
these livers for evidence of UPR activation, whose features and
methods of analysis are well characterized in both animal models
and human liver disease [6]. Also, the mechanistic studies in the
Chouteau paper are limited to interrogation of a few candidate
pathways, whereas a more unbiased analysis using conventional
arrays, deep sequencing and/or proteomics methods could yield
novel insights into the impact of HCV proteins on hepatocytes
and how they interact with other cells.
More intriguing, and also meriting further exploration in the
Chouteau study is the evidence of a brisk progenitor response
and its correlation with reduced hepatocyte proliferation and
increased ﬁbrosis. Our understanding of the relationship between
injury, hepatocyte regeneration and ﬁbrosis remains murky but
ripe for a breakthrough. Study after study continue to demon-
strate a link between ductular reaction, progenitor cells, and
ﬁbrosis, yet the sequence of events and key underlying mediators
are elusive. Epithelial–mesenchymal transition (EMT) is impli-
cated by some, but not all studies as a central driver of this
response, and one candidate mediator in this context may be
the molecule Snail [7]. More reﬁned genetic models to track
and manipulate progenitor cells either in this HCV model or oth-
ers should clarify the meaning of the ductular reaction and the
link between impaired regeneration that activates the progenitor
cell response, and its association with increased ﬁbrosis. Perhaps
this series of events is unique to liver and accounts for its unique
regenerative capacity compared to other tissues.12 vol. 57 j 481–483
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The study by Polasek et al. in this issue of the Journal provides
a scintilla of hope for improved ﬁbrosis assessment using a stan-
dard non-invasive tool, MRI. The investigators explored the utility
of a gadolinium-based contrast agent containing a 16 amino acid
cyclic peptide that speciﬁcally binds collagen, to quantify this
protein in two rodent models of ﬁbrosis. The agent, EP-3533,
was optimized to maintain the highest afﬁnity to collagen while
carrying the largest gadolinium payload [8,9]. The agent was
tested initially in a rat model of weekly DEN for 4 weeks, an unu-
sual dosing scheme for a drug that is typically given only once
intraperitoneally to induce hepatic tumors 6–12 months later.
Thus, this new DEN model of ﬁbrosis itself merits further evalu-
ation, as it appears to reproducibly induce ﬁbrosis and presum-
ably leads to cancer as well. The imaging method was further
evaluated in a CCl4 model in mice treated thrice weekly for
20 weeks, leading to dense cirrhosis. As this was a pilot feasibility
study only single time points were assessed for each model, cor-
relating delayed gadolinium persistence in liver with either
hydroxyproline content (an amino acid unique to collagen) or
Ishak ﬁbrosis score. The correlation coefﬁcient were promising
but not outstanding, and might have been improved if the
authors had correlated the images with either Sirius red staining
or collagen I immunohistochemistry. Moreover, the authors point
out that that the sensitivity of the method would likely be
enhanced when used for clinical studies in humans, where the
magnets used for MRI are more powerful. They also emphasize
that this study was not powered to stage ﬁbrosis, and indeed
the numbers of animals used was small. Still, there is good reason
to further develop this methodology for a number of reasons.
Currently there is no established non-invasive test to quan-
tify ﬁbrosis content that can supplant liver biopsy, despite its
well known limitations, including invasiveness, sampling vari-
ability, and the inability to obtain serial measurements over
time. Therefore, a non-invasive test that could quantify colla-
gen at progressive intervals using a standard technology would
have enormous value not only in clinical practice, but even
before then in clinical trials assessing antiﬁbrotic therapies.
Perhaps the rate of change in collagen content over time could
provide a new, quantitative, and dynamic metric for assessing
both disease progression and regression. Moreover, as the
authors point out, an MRI test for collagen content might be
combined during the same exam with studies to assess fat con-
tent and/or stiffness, providing a more comprehensive assess-
ment of liver structure in complex conditions like non-
alcoholic fatty liver disease.
First, however, more animal data about this gadolinium-based
MRI agent are needed, and then concerns about safety in humans
will need to be thoroughly addressed. Animal studies should be
extended to other models of ﬁbrosis (including biliary ﬁbrosis),
and the collagen content and Sirius red staining must be corre-
lated at several time points in a large number of animals, to con-
ﬁrm that the intensity of the MR signal corresponds exactly to the
amount of hepatic collagen at each stage of disease. Studies in
large animals might lend further support to the value of this
new methodology, for example in pigs, where models of liver dis-
ease have been established [10].
If the technology moves on to human studies, there is linger-
ing concern about the propensity for gadolinium-based contrast
agents to induce nephrogenic systemic ﬁbrosis, especially in
patients with concurrent renal impairment [11]. While the inci-
dence of this syndrome appears to be waning with careful patient482 Journal of Hepatology 201selection, it remains a worry, and perhaps the collagen-binding
cyclic peptide could be linked to a positron emission tomography
(PET)-isotope rather than gadolinium, for PET imaging. Of course,
PET when combined with CT raises concerns about radiation
exposure. Also, patients with very advanced ﬁbrosis and cirrhosis
have intrahepatic shunting and vascular collapse that might
undermine the sensitivity or accuracy of this technology, a pros-
pect that should ﬁrst be addressed in animals by testing the tech-
nology in animals with very advanced ﬁbrosis and portal
hypertension.
The ﬁnal question is whether even a test that measures colla-
gen content perfectly is sufﬁcient for use as a non-invasive diag-
nostic tool. It has become clear that in patients where the
underlying disease is rapidly controlled, for example, in those
treated with antiviral therapy, there may be a lag of up to 2 years
before ﬁbrosis scores improve after the inﬂammation and necro-
sis subside [12]. The ideal ﬁbrosis test would be one that detects
early reductions in ﬁbrogenic activity or increases in proteolytic
activity, which occur well before the actual ﬁbrosis content
changes, yet are accurate harbingers of an improved histology
and ﬁbrosis score at a later interval. This would be an extremely
powerful advance, especially for clinical trials where early evi-
dence of efﬁcacy could incentivize investigators and pharmaceu-
tical sponsors to support long-term trials. Clearly, however, any
MRI test suitable for clinical usage that serially measures collagen
content would represent a major step forward, and could acceler-
ate progress in the staging and treatment of patients with ﬁbrosis
liver disease, particularly those where biopsy is either contraindi-
cated or not available.Conﬂict of interest
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